Research and Development: Comparing Key Metrics for Jazz Pharmaceuticals plc and Dynavax Technologies Corporation

R&D Spending Trends in Biopharmaceuticals: Jazz vs. Dynavax

__timestampDynavax Technologies CorporationJazz Pharmaceuticals plc
Wednesday, January 1, 20148458000085181000
Thursday, January 1, 201586943000135253000
Friday, January 1, 201684493000162297000
Sunday, January 1, 201764988000198442000
Monday, January 1, 201874951000226616000
Tuesday, January 1, 201962331000299726000
Wednesday, January 1, 202028607000335375000
Friday, January 1, 202132228000505748000
Saturday, January 1, 202246600000590453000
Sunday, January 1, 202354886000849658000
Loading chart...

Igniting the spark of knowledge

A Decade of Innovation: R&D Spending in Biopharmaceuticals

In the ever-evolving landscape of biopharmaceuticals, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Jazz Pharmaceuticals plc and Dynavax Technologies Corporation have demonstrated contrasting trajectories in their R&D investments.

From 2014 to 2023, Jazz Pharmaceuticals has consistently increased its R&D expenses, culminating in a staggering 900% growth by 2023. This upward trend underscores Jazz's commitment to expanding its pipeline and enhancing its competitive edge. In contrast, Dynavax Technologies experienced a more volatile R&D spending pattern, with a notable dip in 2020, followed by a gradual recovery. By 2023, Dynavax's R&D expenses had rebounded to approximately 65% of its 2014 levels.

These trends highlight the strategic priorities of each company, with Jazz focusing on aggressive expansion and Dynavax navigating a more cautious path.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025